Bloomberg News

BioCancell Soars Most in 2 Months on FDA ‘Fast Track’ Status

October 04, 2011

(Updates with closing share price in second paragraph.)

Oct. 4 (Bloomberg) -- BioCancell Therapeutics Inc. jumped the most in more than two months after it said the U.S. Food and Drug Administration gave its BC-819 pancreatic-cancer treatment “fast track” status.

The shares advanced 6.3 percent, the biggest gain since Aug. 1, to 1.46 shekels at the 4:30 p.m. close in Tel Aviv, giving the Jerusalem-based company a market value of 39 million shekels ($10.7 million).

--Editors: Susan Lerner, Peter Branton

To contact the reporter on this story: Gwen Ackerman in Jerusalem at gackerman@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net


Monsanto vs. GMO Haters
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus